Company Filing History:
2 out of 169 
1 out of 894 
Years Active: 2016-2022
Title: Abraham Rutenberg: Innovator in Cancer Therapy
Introduction
Abraham Rutenberg is a notable inventor based in Haifa, Israel. He has made significant contributions to the field of immunotherapy, particularly in cancer treatment. With a total of 3 patents, Rutenberg's work focuses on innovative methods that enhance T cell modulation for improved patient outcomes.
Latest Patents
Rutenberg's latest patents include groundbreaking methods for cancer therapy using isolated NTB-A ectodomain polypeptides. This invention is directed towards immunotherapy, providing compositions and methods for improved T cell modulation both ex vivo and in vivo. Specifically, it addresses the treatment of cancer and other pathologies by utilizing soluble NTB-A polypeptides or their agonists. Another significant patent involves cell compositions and methods for cancer therapy, emphasizing the same innovative approaches to T cell modulation and treatment of cytopenia in susceptible patients.
Career Highlights
Throughout his career, Rutenberg has worked with esteemed organizations such as Hadasit Medical Research Services and Development Ltd. and Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. His work in these institutions has furthered research and development in medical technologies.
Collaborations
Rutenberg has collaborated with notable colleagues, including Ronny Uzana and Michal Lotem. These partnerships have contributed to the advancement of his research and the successful development of his patents.
Conclusion
Abraham Rutenberg's innovative work in cancer therapy exemplifies the impact of dedicated research in immunotherapy. His contributions continue to pave the way for advancements in treatment methodologies, ultimately benefiting patients worldwide.